Versican Plus P lyophilisate and solvent for suspension for injection for dogs
Versican Plus P lyophilisate and solvent for suspension for injection for dogs
Authorised
- Canine parvovirus 2b, strain CPV-2b Bio 12/B, Live
Product identification
Medicine name:
Versican Plus P lyophilisate and solvent for suspension for injection for dogs
VERSICAN PLUS P
Active substance:
- Canine parvovirus 2b, strain CPV-2b Bio 12/B, Live
Target species:
-
Dog
Route of administration:
-
Subcutaneous use
Product details
Active substance and strength:
-
Canine parvovirus 2b, strain CPV-2b Bio 12/B, Live3981070.00/tissue culture infective dose 501.00Dose
Pharmaceutical form:
-
Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
-
Subcutaneous use
- Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI07AD01
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Italy
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)
Marketing authorisation holder:
- Zoetis Italia S.r.l
Marketing authorisation date:
Manufacturing sites for batch release:
- Bioveta a.s.
Responsible authority:
- Ministry Of Health
Authorisation number:
- 104899
Date of authorisation status change:
Reference member state:
-
Germany
Procedure number:
- DE/V/0265/001
Concerned member states:
-
Belgium
-
Bulgaria
-
Croatia
-
Cyprus
-
France
-
Greece
-
Hungary
-
Ireland
-
Italy
-
Luxembourg
-
Malta
-
Romania
-
Slovenia
-
United Kingdom (Northern Ireland)
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Combined File of all Documents
English (PDF)
Download Published on: 24/05/2023
Italian (PDF)
Published on: 10/08/2023
How useful was this page?:
